title: Hemodialysis Using High Cut Off Filters in Light Chain Cast Nephropathy.
abstract: OBJECTIVE
  Hemodialysis using high cutoff (HCO) filters possibly improves renal function in diseases with light chain (LC) overproduction and acute kidney injury. We established the effect of HCO dialysis on renal outcome in consecutive patients with malignant monoclonal gammopathies and LC cast nephropathy.
  
  
  METHODS
  LC concentration was measured before and after each dialysis session in 10 patients receiving HCO dialysis and bortezomib-based chemotherapy, and their renal function was monitored by plasma creatinine.
  
  
  RESULTS
  The number of HCO sessions ranged from 4 to 34 (mean 13). Six patients recovered kidney function, 3 regained partial function while 1 patient continued chronic dialysis. Patients with the largest reductions in LC during HCO treatments had the lowest creatinine at 6 and 9 months of follow-up. For comparison, only 2 out of 10 patients in a historic control group recovered kidney function.
  
  
  CONCLUSIONS
  HCO dialysis combined with bortezomib results in good renal recovery with kidney function being dependent on the degree of LC lowering.
authors.affiliation: Department of Renal Medicine, Aarhus University Hospital, Aarhus, Denmark.
authors.forename: Niels Henrik
authors.initials: NH
authors.lastname: Buus
authors.forename: Jesper Moesgaard
authors.initials: JM
authors.lastname: Rantanen
authors.forename: Søren Palmelund
authors.initials: SP
authors.lastname: Krag
authors.forename: Niels Frost
authors.initials: NF
authors.lastname: Andersen
authors.forename: Jens Dam
authors.initials: JD
authors.lastname: Jensen
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000069286:Bortezomib / Q000627:therapeutic use*; D015331:Cohort Studies; D003404:Creatinine / Q000097:blood; D005260:Female; D005921:Glomerulonephritis / Q000097:blood / Q000276:immunology / Q000503:physiopathology / Q000628:therapy*; D018056:Hemorheology; D006801:Humans; D007147:Immunoglobulin Light Chains / Q000097:blood*; D007668:Kidney / Q000276:immunology / Q000378:metabolism / Q000503:physiopathology; D007688:Kidneys, Artificial; D008297:Male; D008567:Membranes, Artificial; D008875:Middle Aged; D010265:Paraproteinemias / Q000097:blood / Q000276:immunology / Q000503:physiopathology / Q000628:therapy*; D020127:Recovery of Function; D006435:Renal Dialysis / Q000295:instrumentation / Q000379:methods*; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D007147:Immunoglobulin Light Chains; D008567:Membranes, Artificial; D000069286:Bortezomib; D003404:Creatinine